mRNA Vaccine Makers Decline After 1,200 Reports of Heart Inflammation Following Shot

June 23, 2021 11:28 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

(Updated - June 23, 2021 12:12 PM EDT)

The CDC, at an advisory panel, said more than 1,200 cases of heart inflammation have been reported in people who received mRNA Covid-19 vaccines.

The news impacted shares of mRNA vaccine makers including Moderna (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX), and Pfizer (NYSE: PFE), along with other vaccine makers like Novavax (NASDAQ: NVAX).

The risk of heart inflammation following vaccination in adolescence and young adults age 12-39 is notably higher after the second vaccine dose, said the CDC.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk